The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Dimethyl fumarate Accord dimethyl fumarate Generic | Accord Healthcare S.L.U. | Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis | 🇪🇺 EU 2023-02-15 | Order → |
| Kauliv teriparatide BiosimilarAdditional monitoring | Strides Pharma (Cyprus) Limited | Osteoporosis; Osteoporosis, Postmenopausal | 🇪🇺 EU 2023-01-12 | Order → |
| Pirfenidone Viatris pirfenidone Generic | Viatris Limited | Idiopathic Pulmonary Fibrosis; Lung Diseases; Respiratory Tract Diseases | 🇪🇺 EU 2023-01-10 | Order → |
| Sugammadex Amomed sugammadex Generic | AOP Orphan Pharmaceuticals GmbH | Neuromuscular Blockade | 🇪🇺 EU 2023-01-10 | Order → |
| Zynlonta loncastuximab tesirine ConditionalAdditional monitoring | Swedish Orphan Biovitrum AB | Lymphoma, Large B-Cell, Diffuse; Lymphoma, B-Cell | 🇪🇺 EU 2022-12-20 | Order → |
| Ebvallo tabelecleucel OrphanPRIMEATMP | Pierre Fabre Medicament | Lymphoproliferative Disorders | 🇪🇺 EU 2022-12-16 | Order → |
| Plerixafor Accord plerixafor Generic | Accord Healthcare S.L.U. | Multiple Myeloma; Hematopoietic Stem Cell Transplantation | 🇪🇺 EU 2022-12-16 | Order → |
| Dimethyl fumarate Teva dimethyl fumarate Generic | Teva GmbH | Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis | 🇪🇺 EU 2022-12-12 | Order → |
| Eladynos abaloparatide Additional monitoring | Theramex Ireland Limited | Osteoporosis, Postmenopausal; Osteoporosis | 🇪🇺 EU 2022-12-12 | Order → |
| Livmarli maralixibat chloride OrphanExceptional circumstancesAdditional monitoring | Mirum Pharmaceuticals International B.V. | Alagille Syndrome | 🇪🇺 EU 2022-12-09 | Order → |
| Locametz gozetotide | Novartis Europharm Limited | Radionuclide Imaging | 🇪🇺 EU 2022-12-09 | Order → |
| Pemetrexed Baxter pemetrexed Generic | Baxter Holding B.V. | Carcinoma, Non-Small-Cell Lung; Mesothelioma | 🇪🇺 EU 2022-12-09 | Order → |
| Pluvicto lutetium (177Lu) vipivotide tetraxetan Additional monitoring | Novartis Europharm Limited | Prostatic Neoplasms, Castration-Resistant | 🇪🇺 EU 2022-12-09 | Order → |
| Spevigo spesolimab ConditionalAdditional monitoring | LEO Pharma A/S | Psoriasis | 🇪🇺 EU 2022-12-09 | Order → |
| Qdenga dengue tetravalent vaccine (live, attenuated) Additional monitoring | Takeda Pharmaceuticals International AG Ireland Branch | Dengue | 🇪🇺 EU 2022-12-05 | Order → |
| Mycapssa octreotide | Amryt Pharmaceuticals DAC | Acromegaly | 🇪🇺 EU 2022-12-02 | Order → |
| Teriparatide Sun teriparatide | Sun Pharmaceutical Industries Europe B.V. | Osteoporosis; Osteoporosis, Postmenopausal | 🇪🇺 EU 2022-11-18 | Order → |
| Enjaymo sutimlimab OrphanAdditional monitoring | Recordati Rare Diseases | Hemolysis; Anemia, Hemolytic, Autoimmune | 🇪🇺 EU 2022-11-15 | Order → |
| VidPrevtyn Beta COVID-19 Vaccine (recombinant, adjuvanted) Additional monitoring | Sanofi Pasteur | COVID-19 virus infection | 🇪🇺 EU 2022-11-10 | Order → |
| Livtencity maribavir OrphanAdditional monitoring | Takeda Pharmaceuticals International AG Ireland Branch | Cytomegalovirus Infections | 🇪🇺 EU 2022-11-09 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.